ABVC Biopharma Inc Market Cap ($26.26 Million)
Market Cap & Net Worth: ABVC Biopharma Inc (ABVC)
ABVC Biopharma Inc market cap. ABVC Biopharma Inc (NASDAQ:ABVC) has a market capitalization of $26.26 Million ($26.26 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24034 globally and #5202 in its home market, demonstrating a -6.18% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ABVC Biopharma Inc's stock price $0.99 by its total outstanding shares 26654365 (26.65 Million). Also see how efficiently does ABVC Biopharma Inc generate cash for how efficiently the company converts equity into cash flow.
ABVC Biopharma Inc Market Cap History (2016–2026)
ABVC Biopharma Inc market cap history from 2016 to 2026. Data shows change from $9.60 Billion to $26.26 Million (-49.06% CAGR). Check ABVC Biopharma Inc stock quote for real-time trading data and today's change.
Index Memberships
ABVC Biopharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #678 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2241 of 3165 |
Weight: ABVC Biopharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ABVC Biopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ABVC Biopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ABVC Biopharma Inc (ABVC) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
71.33x
ABVC Biopharma Inc's market cap is 71.33 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $9.60 Billion | $32.00 | -$11.01 Million | 299861273.07x | N/A |
| 2017 | $9.60 Billion | $3.20K | -$4.24 Million | 3002365.69x | N/A |
| 2018 | $9.60 Billion | $6.96K | -$5.58 Million | 1379465.32x | N/A |
| 2019 | $1.16 Billion | $701.72K | -$3.64 Million | 1659.92x | N/A |
| 2020 | $1.36 Billion | $483.05K | -$9.79 Million | 2814.17x | N/A |
| 2021 | $903.58 Million | $355.80K | -$12.84 Million | 2539.60x | N/A |
| 2022 | $166.59 Million | $969.78K | -$16.42 Million | 171.78x | N/A |
| 2023 | $30.92 Million | $152.43K | -$7.79 Million | 202.84x | N/A |
| 2024 | $15.73 Million | $509.59K | -$4.90 Million | 30.86x | N/A |
| 2025 | $56.77 Million | $795.95K | -$7.91 Million | 71.33x | N/A |
Competitor Companies of ABVC by Market Capitalization
Companies near ABVC Biopharma Inc in the global market cap rankings as of November 4, 2026. Also see ABVC Biopharma Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to ABVC Biopharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of ABVC Biopharma Inc (2016–2026)
Market capitalization of ABVC Biopharma Inc from 2016 to today. Between 2016 and today, ABVC Biopharma Inc's market cap moved from $9.60 Billion to $ 26.26 Million, with a yearly change of -49.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $26.26 Million | -53.75% |
| 2025 | $56.77 Million | +261.02% |
| 2024 | $15.73 Million | -49.14% |
| 2023 | $30.92 Million | -81.44% |
| 2022 | $166.59 Million | -81.56% |
| 2021 | $903.58 Million | -33.53% |
| 2020 | $1.36 Billion | +16.70% |
| 2019 | $1.16 Billion | -87.86% |
| 2018 | $9.60 Billion | 0.00% |
| 2017 | $9.60 Billion | 0.00% |
| 2016 | $9.60 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of ABVC Biopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.26 Million USD |
| MoneyControl | $26.26 Million USD |
| MarketWatch | $26.26 Million USD |
| marketcap.company | $26.26 Million USD |
| Reuters | $26.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ABVC Biopharma Inc
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II … Read more